Paul R. Gavine

Statistics

Publications

Citations

2.2K

H-Index

Active since

1999

Affiliations

Shanghai Innovative Research Center of Traditional Chinese Medicine(Current)

AstraZeneca (United Kingdom)

Shanghai Jiao Tong University

Renji Hospital

The First Affiliated Hospital, Sun Yat-sen University

Paul R. Gavine is an author at Shanghai Innovative Research Center of Traditional Chinese Medicine specializing in medicine, tumor biology, and cell biology.

ORCID

Top concepts

MedicineCell BiologyTumor BiologyCancer ResearchTumor MicroenvironmentOncologyPathologyMolecular DiagnosticsRadiation OncologyPharmacology

Publications per year

1999–2023

Publications

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 491 citations

Fgfr Selectivity, Kinase Inhibitors, Pharmacotherapy +16

<i>FGFR2</i> Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

Liang Xie, Xinying Su, Lin Zhang et al. · Clinical Cancer Research · 2013 · 236 citations

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

Xin Su, Ping Zhan, Paul R. Gavine et al. · British Journal of Cancer · 2014 · 183 citations · Full text

Translating the Therapeutic Potential of AZD4547 in <i>FGFR1</i> -Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Jingchuan Zhang, Lin Zhang, Xinying Su et al. · Clinical Cancer Research · 2012 · 155 citations

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 155 citations · Full text

1–5 of 26